Optimize Your Portfolio, Today
Experience frustration-free portfolio strategy
Harness the power of AI for drug development to transform decision-making and optimize your pipeline. Intelligencia AI equips pharmaceutical companies with data-driven tools to enhance efficiency, reduce costs, and improve outcomes.
Optimize PTRS With AI
Predict Drug Success With AI
Drive Objective Based Decisions
Revolutionizing Drug Development With AI
Harness the power of AI for drug development to transform decision-making and optimize your pipeline. Intelligencia AI equips pharmaceutical companies with data-driven tools to enhance efficiency, reduce costs, and improve outcomes.
Let's Talk
Predicting Drug Success With AI
With Intelligencia AI you can reduce the uncertainty of drug development with tools that deliver actionable insights and improve decision accuracy.
Evaluate Pipeline Options
Compare internal pipeline opportunities with the competitive landscape tapping AI to identify the best path forward.
Greater Visibility Into Approval Probability
Focus on What Matters

“AI is very good at telling you A is better than B or vice versa. Even a small benefit from AI can be a good return on investment. If you just move the needle by a fraction of a percent of the probability of success, you’ve paid for your service 10 times, 30 times, 50 times, 100 times. The risk of not investing in AI is far greater than investing in it and learning.”
– VP, Head of Global Portfolio Management, Valuation & Analytics

Access Unbiased, AI-driven PTRS Assessments
Having an accurate and reliable AI-driven probability of technical and regulatory success (PTRS) is vital for pharmaceutical companies when it comes to elevating decision-making and reducing risks.
Improve Risk Assessments
Gain Strategic Insights
Maximize Return on Investment

Reduce Drug Development Costs With AI
Reducing costs without compromising innovation is essential in today’s pharmaceutical landscape. Intelligencia AI provides tailored AI and machine learning for drug development solutions to address this challenge.